From vaccine developers to pharma corporations: The most important German companies in the battle against the corona pandemic are to be found in Frankfurt RheinMain.
To date, BioNTech has focused on individual cancer immune therapies. Since the beginning of the corona pandemic, CEO and co-founder Ugur Sahin (photo) has pursued a single goal: to make a vaccine against Sars-CoV-2 available worldwide as soon as possible. Founded in 2008, the biotech company, which is headquartered in Mainz, required less than three months to get potential vaccines into the clinical phase. Like cancer therapies, the vaccine is based on a so-called messenger RNA (mRNA), and BioNTech aims to market a vaccine by the end of 2020. During development, the company has collaborated with big players in the sector: French pharma corporation Sanofi, US pharma corporation Pfizer and China’s conglomerate Fosun. Moreover, BioNTech is working with the Bill & Melinda Gates Foundation to develop vaccines against HIV and tuberculosis – and since October 2019 has been listed on Nasdaq, the US tech exchange.